UOC
ARQT icon

UBS O'Connor’s Arcutis Biotherapeutics ARQT Stock Holding History

UBS O'Connor’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,201
Closed -$206K – 379
2025
Q1 		$206K Sell
13,201
-64,354
-83% -$907K ﹤0.01% 249
2024
Q4 		$1.08M Sell
77,555
-14,464
-16% -$158K 0.03% 222
2024
Q3 		$856K Buy
+92,019
New +$908K 0.02% 295
2022
Q3 		– Sell
-66,635
Closed -$1.42M – 962
2022
Q2 		$1.42M Buy
66,635
+31,370
+89% +$643K 0.01% 720
2022
Q1 		$679K Buy
+35,265
New +$597K 0.01% 734

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

UBS O'Connor's ARQT Position: Q2 2025 in Review

UBS O'Connor sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 13,201 shares — an estimated $206K sold.

UBS O'Connor first reported a position in ARQT in Q1 2022 and held it in 5 quarters. The position peaked at $1.42M in Q2 2022. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • UBS O'Connor reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 13,201 Arcutis Biotherapeutics shares in Q2 2025, an estimated $206K.
  • UBS O'Connor first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 5 quarters.
  • UBS O'Connor's Arcutis Biotherapeutics position peaked at $1.42M in Q2 2022.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.